8 October 2021
EMA/CVMP/521675/2021
Committee for Medicinal Products for Veterinary Use

Summary of opinion[1] (post-authorisation)

NexGard Combo

International non-proprietary name (INN): esafoxolaner / eprinomectin / praziquantel

On 7 October 2021, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion[2], recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product NexGard Combo. The marketing authorisation holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.

NexGard Combo is currently authorised as spot-on solution for the treatment of mixed infections by cestodes, nematodes and ectoparasites. This grouped variation concerns the addition of new therapeutic indications for the treatment of notoedric mange (caused by *Notoedres cati*), the treatment of infections with *Aelurostrongylus abstrusus* (L3, L4 larvae and adults) and prevention of aelurostrongylosis in cats; and to support the safe use of the product in breeding, pregnant and lactating queens.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000
An agency of the European Union